Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of five cardiovascular agents—epinephrine, norepinephrine, dobutamine, dopamine, and levosimendan—used for advanced hemodynamic support in critical care settings. Each component acts as a positive inotrope or vasopressor with distinct mechanisms: - Epinephrine and norepinephrine are endogenous catecholamines that stimulate adrenergic receptors to increase cardiac output and vascular tone. - Dobutamine is a synthetic catecholamine primarily stimulating beta-1 adrenergic receptors to enhance myocardial contractility. - Dopamine acts on dopaminergic and adrenergic receptors depending on dose, providing both inotropic support and vasoconstriction. - Levosimendan is an inodilator that increases cardiac contractility by sensitizing troponin C to calcium (without increasing intracellular calcium) and causes vasodilation by opening ATP-sensitive potassium channels[1][2][3]. This combination may be considered for patients with severe acute or decompensated heart failure or shock states unresponsive to standard therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epinephrine + norepinephrine + dobutamine + dopamine + levosimendan.